Generex Biotechnology to accelerate development of vaccine for pandemic avian influenza
Novel vaccine technology boosting T helper cell response to Asian bird flu influenza promises increased population protection
21-Oct-2005 -
Generex Biotechnology Corporation announced that Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, has re-organized its forces to speed development of a novel vaccine to protect against the H5N1 avian influenza. In particular, the President of Antigen Express, Eric von Hofe, ...
antibodies
avian influenza
breast cancer
+6